Skip to main content

Table 1 The clinical features of gastric cancer patients in the model group and validation group

From: Integrated analysis reveals potential long non-coding RNA biomarkers and their potential biological functions for disease free survival in gastric cancer patients

 

Model group (n = 265)

Validation group (n = 300)

P value

Death [n (%)]

98 (37.0)

161 (53.7)

< 0.001

Survival time (mean ± SD, month)

20.6 ± 18.8

33.7 ± 29.8

0.008

Age (mean ± SD, year)

64.4 ± 10.6

61.9 ± 11.4

< 0.001

Male [(n) %]

175 (66.0)

199 (66.3)

0.941

AJCC Stage (IV/III/II/I/NA)

23/103/91/41/7

77/95/98/30/0

< 0.001

AJCC PT (T4/T3/T2/T1/NA)

66/121/62/16/0

21/91/188/0/0

< 0.001

AJCC PN (N4/N3/N2/N1/N0/NA)

4/49/55/67/88/2

0/51/80/131/38/0

0.011

AJCC PM (M2/M1/M0/NA)

9/13/243/0

0/27/273/0

0.869

Targeted molecular therapy (yes/no/NA)

78/79/108

NA

 

Radiation treatment adjuvant (yes/no/NA)

0/155/110

NA

 

History other malignancy (yes/no/NA)

6/259/0

NA

 

Barretts esophagus (yes/no/NA)

12/151/102

NA

 

H pylori infection (yes/no/NA)

15/117/133

NA

 
  1. Continuous variables were compared by t-test or Mann–Whitney U test as appropriate; categorical variables were compared by Chi squared test or Fisher’s exact test as appropriate
  2. NA, missing data; SD: standard deviation; AJCC: American Joint Committee on Cancer